- AE
adverse event
- ALT
alanine aminotransferase
- A-P
amitriptyline supplemented with pregabalin
- AST
aspartate aminotransferase
- BNF
British National Formulary
- BPI-MSF
Brief Pain Inventory – Modified Short Form
- CI
confidence interval
- CRF
case report form
- CSRI
Client Service Receipt Inventory
- CTRU
Clinical Trials Research Unit
- DMEC
Data Monitoring and Ethics Committee
- DN4
Douleur Neuropathique 4
- D-P
duloxetine supplemented with pregabalin
- DPNP
diabetic peripheral neuropathic pain
- eGFR
estimated glomerular filtration rate
- EQ-5D
EuroQol-5 Dimensions
- EQ-5D-5L
EuroQol-5 Dimensions, five-level version
- GP
general practitioner
- HADS
Hospital Anxiety and Depression Scale
- HbA1c
glycated haemoglobin
- HRQoL
health-related quality of life
- ICER
incremental cost-effectiveness ratio
- IMP
investigational medicinal product
- ISI
Insomnia Severity Index
- mTCNS
modified Toronto Clinical Neuropathy Score
- NICE
National Institute for Health and Care Excellence
- NPSI
Neuropathic Pain Symptom Inventory
- NRS
Numeric Rating Scale
- OPTION-DM
Optimal Pathway for TreatIng neurOpathic paiN in Diabetes Mellitus
- P-A
pregabalin supplemented with amitriptyline
- PGIC
Patient Global Impression of Change
- PI
principal investigator
- PPI
patient and public involvement
- QALY
quality-adjusted life-year
- QoL
quality of life
- RCT
randomised controlled trial
- SAE
serious adverse event
- SCRAM
Sheffield Clinical Trials Research Unit online randomisation system
- SD
standard deviation
- SF-36
Short Form questionnaire-36 items
- SMS
short message service
- SSRI
selective serotonin reuptake inhibitor
- SUSAR
suspected unexpected serious adverse reaction
- TMG
Trial Management Group
- TSC
Trial Steering Committee
